Otsuka, Lundbeck to Carry On Multinational PIII of Brexpiprazole for Agitation in Alzheimer’s

Otsuka Pharmaceutical and its Danish partner Lundbeck said on April 13 that they have decided to continue a multinational PIII study of the antipsychotic agent brexpiprazole (Rexulti/Rxult), seeking an additional indication for the treatment of agitation in patients with Alzheimer’s...read more